Solid Biosciences Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $8.1M | $13.6M |
| Research and development | $140.3M | $96.4M | $76.6M | $78.4M | $58.7M |
| Operating expenses | $179.2M | $129.7M | $104.3M | $114.5M | $85.9M |
| Operating income | -$179.2M | -$129.7M | -$104.3M | -$106.5M | -$72.3M |
| Interest expense | $203,000 | $340,000 | $440,000 | — | — |
| Pretax income | -$174.2M | -$124.6M | — | — | — |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$174.3M | -$124.7M | -$96.0M | -$86.0M | -$72.2M |
| Balance Sheet | |||||
| Cash and equivalents | $59.9M | $80.2M | $74.0M | $155.4M | $119.1M |
| Current assets | $205.5M | $157.3M | $129.7M | $219.6M | $222.6M |
| Total assets | $232.5M | $188.7M | $164.9M | $260.3M | $232.4M |
| Current liabilities | $33.5M | $30.3M | $14.5M | $22.5M | $23.6M |
| Total liabilities | $52.5M | $51.4M | $38.5M | $48.6M | $24.2M |
| Stockholders' equity | $180.0M | $137.2M | $126.5M | $211.7M | $208.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$156.3M | -$100.0M | -$94.2M | -$98.0M | -$77.8M |
| Depreciation and amortization | $1.6M | $2.5M | $2.6M | $2.4M | $3.0M |
| Stock-based compensation | $16.9M | $10.5M | $7.6M | $7.5M | $13.4M |
| Capital expenditure | $1.2M | $654,000 | $1.5M | $3.0M | $1.3M |
| Free cash flow | -$157.4M | -$100.7M | -$95.7M | -$101.0M | -$79.0M |
| Impairments | — | $0 | $400,000 | $0 | $92,000 |
Shares outstanding 98.4M · Free float 52.1%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.